linjc16/ctgov huggingface dataset:
CTC in Lung Caner Patients With Bone Metastases

Study Overview
=================
Brief Summary
-----------------
Evaluate the feasibility of single cell sequencing technology based on three-dimensional bionic capture network; To build a risk prediction model of bone related events based on single cell sequencing; To verify the risk prediction model of bone related events by single cell sequencing; To verify the comprehensive treatment of non-small cell lung cancer ( NSCLC) bone metastases.

Official Title
-----------------
Clinical Reasearch on Three Dimensional Bionic Capture Network Circulating Tumor Cell in Lung Caner Patients With Bone Metastases

Conditions
-----------------
Lung Cancer, Bone Metastases, Single Cell Sequencing Technology

Intervention / Treatment
-----------------
* Other: model treatment
* Other: routine treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-75 years pathology-proven diagnosis of lung cancer and radiographical/pathological evidence of BM no previous treatment for BM good general condition (Eastern Cooperative Oncology Group, ECOG Performance scores: 0-2) with an estimated survival time > 3 months. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: routine treatment<br>routine treatment | Other: routine treatment<br>* the treatment decisions were decided by multi-disciplinary team （MDT）<br>|
| Experimental: model treatment<br>model treatment | Other: model treatment<br>* the treatment decisions were decided by Machine Learning （ML） model in model treatment group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SREs（Skeletal related events） | occurance of SREs，including bone pain, pathological fractures, spinal cord compression, hypercalcemia, and the need for surgery or radiotherapy | 1 year |
Minimally Invasive Sinus Lift Through the Interradicular Septum

Study Overview
=================
Brief Summary
-----------------
This study aims to describe a new approach for the reconstruction of the alveolar process in the sinus area. This minimally invasive approach will access the maxillary sinus through the alveolar process, elevating the sinus membrane in the area immediately above it. The regeneration may be achieved in the specific area required for dental implant placement, reducing the morbidity of the procedure.

Official Title
-----------------
Minimally Invasive Microsurgical Sinus-lift Through the Interradicular Septum. A Clinical Trial

Conditions
-----------------
Bone Loss, Bone Loss, Age-related, Atrophy; Alveolar Process, Surgical Procedure, Unspecified

Intervention / Treatment
-----------------
* Procedure: Interradicular septum window


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient older than 18 years. Plaque index and bleeding index less than 30%. Invagination of the sinus cavity in the interradicular area of the upper first molar. Upper first molar not restorable and with height of the interradicular remnant less than 5 mm. Exclusion Criteria: Presence of systemic disease contraindicating the intervention. Pregnant women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>After the molar extraction, no intervention will be performed. | |
| Experimental: Interradicular septum window group<br>After the extraction of the molar, the maxillary sinus membrane will be elevated through a micro-window, previously done in the interradicular septum. | Procedure: Interradicular septum window<br>* In this group, the maxillary sinus will be accessed through a window in the interradicular septum and the membrane will be elevated, carrying out the regeneration of the area to facilitate subsequent implant placement.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone height | Bone height change | 9 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bucco-palatal bone width | Bucco-palatal bone width change | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
maxillary sinus, sinus lift, xenograft
Evaluation of Prognosis and Prognostic Scores in Geriatric Patients With Acute Pancreatitis

Study Overview
=================
Brief Summary
-----------------
To compare the prognosis of acute pancreatitis between geriatric and other adult patients To evaluate the efficacy of various prognostic scores in geriatric patients with acute pancreatitis

Official Title
-----------------
Evaluation of Prognosis and Prognostic Scores in Geriatric Patients With Acute Pancreatitis: A Prospective Cohort Study

Conditions
-----------------
Acute Pancreatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute pancreatitis Hospitalisation Adult patients Exclusion Criteria: Recurrent pancreatitis Chronic pancreatitis Outpatient follow up Loss of follow up within 3 months of discharge

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Elderly, acute pancreatitis<br>No intervention | |
| Adults <65 y, acute pancreatitis<br>No intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rate in geriatric patients with acute pancreatitis |  | Within 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morbidity rate in geriatric patients with acute pancreatitis |  | Within 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Elderly, Prognosis
Effects of Anaesthesia on Inflammatory Markers

Study Overview
=================
Brief Summary
-----------------
undertake confidently both open and laparoscopic cholecystectomy. Major types of body injuries surgical or accidental; evoke a temporary, yet predictable systemic inflammatory response caused by hormonal, immunological and metabolic mediators. This inflammatory response is essential for tissue repair and has evolved to maximize the organisms' healing potential. In healthy individuals the inflammatory response to major surgery is well balanced consisting of pro- and anti-inflammatory mediators. The severity of injury, the occurrence of surgical complications and its accompanying level of stress may hinder the balance of the inflammatory response6.

Official Title
-----------------
Effects of Anesthetics on Inflammatory Markers in Patients Undergoing Abdominal Surgeries.

Conditions
-----------------
Inflammatory Response

Intervention / Treatment
-----------------
* Drug: Morphine Sulfate
* Drug: morphine+lidocaine
* Drug: Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients aging 18 - 55 years old Patients scheduled for abdominal surgeries Patients with American Society of Anesthesiologists (ASA) I, II physical status Exclusion Criteria: Patients' refusal. Critically ill patients. Patients who have contraindications to regional anesthesia.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: G-M<br>Received classic general Anesthesia, intrathecal (Bupivacaine 15 mg, morphine 4 microgram/kg) plus saline infusion intraoperative and postoperative. | Drug: Morphine Sulfate<br>* intrathecal morphine will be added to anaesthetics<br>|
| Active Comparator: G-ML<br>Received classic general Anesthesia, intrathecal morphine in a dose of 4 microgram/kg, and intravenous lidocaine in a loading dose of 1.5 mg/kg, then 2 mg/min with the saline infusion over the time of the operation and the next 4 hours postoperative. | Drug: morphine+lidocaine<br>* local anesthetic will be infused intravenously<br>|
| Placebo Comparator: G-0<br>Received General Anesthesia and Spinal anesthesia as previously described with saline infusion in the same design as in the previous two groups. | Drug: Saline<br>* intravenous saline infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analogue score | a scale to measure pain intensity graded from 0 = no pain to 10 = worst pain | 24 hours |
Treatment of Copper Intra Uterine Device Associated Heavy Menstrual Blood Loss

Study Overview
=================
Brief Summary
-----------------
Intrauterine contraceptive device is the most commonly reversible method used among women of reproductive age worldwide. Almost one in five married contraceptive users is currently using Intrauterine contraceptive device. The Egyptian demographic and health survey results indicate that 30% of currently married women interviewed in the Egyptian demographic and health survey were using Intrauterine contraceptive device. Main reasons for discontinuation of Intrauterine contraceptive device as cited by women were excessive bleeding per vagina 39.68%, abdominal pain 38.62%, low backache35.97%.

Official Title
-----------------
Tranexamic Acid Versus Calcium Dobesilate for the Treatment of Copper Intra Uterine Contraceptive Device Associated Heavy Menstrual Blood Loss : A Randomized , Open-labelled , Clinical Trial.

Conditions
-----------------
Menorrhagia

Intervention / Treatment
-----------------
* Drug: Tranexamic Acid 500 MG
* Drug: Calcium Dobesilate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women usingsopperT380A and reporting heavy menstrual blood loss during use. Menorrhagia , will be defined as a Pictorial blood loss assessment chart-Score greater than 100. No contraindication to drugs used in treatment. No other cause for heavy menstrual blood loss Exclusion Criteria: Refusing to participate. Irregular menstrual cycle. Misplaced Intrauterine device.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Tranexamic Acid<br>Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle till the end of bleeding for 3 cycles | Drug: Tranexamic Acid 500 MG<br>* oral tablets<br>|
| Experimental: Calcium Dobesilate<br>Calcium Dobesilate oral tablets 500 mg (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding. | Drug: Calcium Dobesilate<br>* oral tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of women requesting treatment for heavy menstrual blood loss. |  | 3 months |
Clinical Efficacy and Safety of Benjakul Recipe in Treating Primary Osteoarthritis of Knee Compared With Diclofenac

Study Overview
=================
Brief Summary
-----------------
Efficacy and adverse effects of Benjakul recipe in Treating Primary Osteoarthritis of Knee Compared with Diclofenac. This study was designed as double blind, randomized controlled trial. Approval from the ethical committee of Human Research Ethics Committee of Thammasat University (No: 1 Faculty of Medicine)

Official Title
-----------------
Clinical Efficacy and Safety of Benjakul Recipe in Treating Primary Osteoarthritis of Knee Compared With Diclofenac (Clinical Trial Phase II)

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Drug: Benjakul recipe
* Drug: diclofenac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with primary osteoarthritis of knee with grade I-III of Kellgren & Lawrence criteria Not during breast feeding Not during pregnancy with a good contraception Volunteer have a normal Complete Blood Count laboratory, lipid profiles,liver function tests and renal funtion tests Do not abuse drugs Good cooperation Exclusion Criteria: BMI > 32 History of peptic ulcer, Gastroesophageal reflux disease (GERD), heart disease, liver disease or kidney disease History of allergy diclofenac or allergy herbal medicine

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Benjakul | Drug: Benjakul recipe<br>* Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days<br>|
| Active Comparator: 2<br>diclofenac | Drug: diclofenac<br>* diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score | Pain score from Visual analog scale | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score | Pain score from Modified WOMAC score (from Modified Thai WOMAC index) | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoarthritis of The knee, Benjakul, Alternative Medicine
Treatment of Acetabular Fracture: the Contribution of the 3D Impression

Study Overview
=================
Brief Summary
-----------------
Acetabular fracture are common in elder patients and high energy trauma in younger one. However, the fracture deplacement induces incongruity between cotyloid cavity and femoral head. Anatomic reduction and osteosynthesis of these fracture are technically difficult . 3D printing ease the process of operating planification or implant fabrication. The 3D impression allows to obtain a model on the scale of the pond of the patient allowing to pre mold plates on the anatomy of the patient before he is operated with the aim of decreasing the surgical time and improving the quality of the reduction.

Official Title
-----------------
Treatment of Acetabular Fracture: the Contribution of the 3D Impression

Conditions
-----------------
Acetabular Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >18 acetabulum fracture within one month anterior access or double access Exclusion Criteria: acetabulum fracture more than one month

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| operating room time |  | day1 |
Effect of Gabapentin on Pain of the Second Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
Gabapentin pretreatment may reduce hyperalgesia occurring at the second surgery in serial, bilateral cataract surgery.

Detailed Description
-----------------
Hyperalgesia occurring at the second operation in bilateral eye surgery is well known, and mechanism of central sensitization might be involved. Gabapentin is known to lower the effect of central sensitization, and its effect on acute postoperative pain has been reported. Therefore, pretreatment of gabapentin after first operation may reduce the pain at second operation.

Official Title
-----------------
The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery

Conditions
-----------------
Hyperalgesia

Intervention / Treatment
-----------------
* Drug: gabapentin
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient of ASA(American Cociety of Anesthesiology) class I, II, III between age 20 to 80, scheduled for serial bilateral cataract surgery(1 weel interval) Exclusion Criteria: refuse to participate BMI<16 or BMI >30 severe cardiovascular, pulmonary, renal disease alcohol or drug abuse currently taking CNS(central nervous system) inhibitory drugs taking antiacids depressive disorder pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gabapentin<br>gabapentin pretreatment | Drug: gabapentin<br>* 100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery<br>|
| Placebo Comparator: Placebo<br>placebo drug pretreatment | Drug: placebo<br>* the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proportion of subjects who answer that pain was greater in the second eye surgery |  | Intra operative (pain while fluid injection to anterior chamber) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| perioperative pain | evaluation of overall perioperative pain | end of surgery, post-op 1hr at PACU, at out-patient ward, post-op 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
central sensitization, serial cataract surgery, hyperalgesia, gabapentin
Cardiovascular Protective Effect of Spironolactone in Hemodialysis

Study Overview
=================
Brief Summary
-----------------
The purpose of the present study is to determine if spironolactone is safe and effective in the treatment of cardiovascular complications in hemodialysis patients.

Detailed Description
-----------------
Cardiovascular complications are common in dialysis patients and comprise up to 50% of deaths in end-stage renal disease population. Hypertension and left ventricle hypertrophy occur in more than 70% of patients undergoing long-term hemodialysis therapy, and both contributes to mortality and morbidity.Recent clinical trials in chronic heart failure and post miocardial infarct heart failure patients have demonstrated a beneficial effect of a mineralocorticoid receptor blocker spironolactone, in adittion to standard therapy (RALES AND EPHESUS studies). The aim of the present study is to evaluate spironolactone treatment in hemodialysis patients.

Official Title
-----------------
Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies

Conditions
-----------------
Hemodialysis

Intervention / Treatment
-----------------
* Drug: Spironolactone (drug)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic hemodialysys (> 3 months) anuria (diuresis <200 mL/day) - Exclusion Criteria: Liver failure Insulin dependent diabetes Treatment with adrenergic beta blockers or agonists Treatment with converting-enzime blocker or angiotensin receptor antagonists Cancer -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Spironolactone (drug)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aldosterone, hemodialysis, heart failure, spironolactone